Trial Profile
An exploratory clinical study of Anlotinib combined with meso-4-1bb-cd3 ? - a PD1 car T cells in the treatment of recurrent and refractory ovarian cancer
Status:
Not yet recruiting
Phase of Trial:
Phase 0
Latest Information Update: 02 Dec 2020
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; CAR-T cell therapies
- Indications Ovarian cancer
- Focus Adverse reactions
- 02 Dec 2020 New trial record